vvn461
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2023 (NCT06906198)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07136805 | Phase 3 | Oct 1, 2025 | VivaVision Biotech, Inc |
| NCT06164743 | Phase 2 | Jan 1, 2024 | VivaVision Biotech, Inc |
| NCT06679153 | Phase 2 | Nov 27, 2023 | VivaVision Biotech, Inc |
| NCT06906198 | Phase 1 | Mar 1, 2023 | VivaVision Biotech, Inc |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VivaVision Biotech, Inc | For profit | 4 | 4 | 3 | 2023 |
1 organizations
Page 1 / 1